相关实验视频

Updated: Jun 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

在前列腺癌中使用niraparib/abiraterone乙酸盐的副作用管理算法

Jean-Baptiste Lattouf¹, Jenny J Ko², Margot K Davis³

¹Department of Surgery-Urology, CHUM-Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.

The Canadian journal of urology

|October 27, 2024

概括

在转移性割抵抗性前列腺癌 (mCRPC) 中,尼拉巴里布/阿比拉酸盐加上普得尼松/普得尼索隆 (尼拉巴里布/AA+P) 的管理算法解决了贫血和高血压等常见副作用. 策略包括剂量调整和药物测序,以改善患者护理.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

尼拉巴里布是一种PARP1/2抑制剂,已被批准与阿比拉特酸盐 (AA) 加上普雷迪松/普雷迪松 (尼拉巴里布/AA+P) 用于治疗BRCA突变的转移性割抵抗性前列腺癌 (mCRPC).
临床实践可能会受益于关于管理这种联合治疗的副作用和剂量的详细指导.

研究的目的:

在mCRPC中开发与niraparib/AA+P相关的常见不良事件 (AE) 的管理算法.
为加拿大临床医生提供监测,治疗调整和转诊的实用指南,以管理与niraparib/AA+P相关的副作用.

主要方法:

一个由专家组成的小组设计了针对贫血,血小板缩,高血压和恶心的管理算法.
算法基于加拿大卫生部批准的niraparib/AA+P的处方信息.

主要成果:

专家小组的建议通常与niraparib/AA+P产品专著一致.
管理更高级别的副作用的常见策略包括暂时停止尼拉帕里布/AA+P治疗,并以较低剂量重新开始治疗.
高血压管理建议强调在改变抗癌疗法之前进行连续的抗高血压药物试验.

结论:

开发的算法为加拿大临床医生提供实用支持,在mCRPC患者中管理频繁的AE,这些患者接受了niraparib/AA+P治疗.
这些指导方针旨在优化这种新型组合疗法的患者护理和治疗坚持.

关键词:

这是一种PARP抑制剂.不良事件不良事件不良事件算法算法是一种算法.贫血贫血是一种疾病.抗割的抗割材料这种高血压,高血压.恶心恶心恶心尼拉帕里布里布里布.前列腺新生体前列腺瘤.血小板细胞减少症 (Thrombocytopenia) 是一种

更多相关视频

Serum and Plasma Copy Number Detection Using Real-time PCR

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...